| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 |
| Sales | 13,210 | 11,570 | 11,210 | 9,170 | 8,260 |
| Sales Growth | +14.17% | +3.21% | +22.25% | +11.02% | +12.38% |
| Net Income | -9,750 | -10,810 | -8,290 | -10,380 | -10,100 |
| Net Income Growth | +9.81% | -30.40% | +20.13% | -2.77% | -320.83% |
Trisalus Life Sciences Inc (TLSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
TriSalus Life Sciences Inc. is an oncology company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. TriSalus Life Sciences Inc., formerly known as MedTech Acquisition Corporation, is based in CHICAGO.
Fiscal Year End Date: 12/31